A Phase IIa Open-label Trial to Investigate the Early Bactericidal Activity, Safety and Tolerability of GSK3036656 in Participants With Drug-sensitive Pulmonary Tuberculosis
Phase of Trial: Phase II
Latest Information Update: 26 Jun 2019
Price : $35 *
At a glance
- Drugs GSK 3036656 (Primary) ; Rifampicin/isoniazid/pyrazinamide/ethambutol
- Indications Pulmonary tuberculosis
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 21 Jun 2019 Planned End Date changed from 13 Oct 2020 to 8 Sep 2020.
- 21 Jun 2019 Planned primary completion date changed from 1 Oct 2020 to 8 Sep 2020.
- 21 Jun 2019 Status changed from not yet recruiting to recruiting.